Compare SKIL & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | ACET |
|---|---|---|
| Founded | 1998 | 1947 |
| Country | United States | United States |
| Employees | 2261 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 69.6M |
| IPO Year | N/A | 2017 |
| Metric | SKIL | ACET |
|---|---|---|
| Price | $3.71 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | ★ 148.0K | 130.1K |
| Earning Date | 01-01-0001 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.72 | $0.45 |
| 52 Week High | $23.00 | $9.05 |
| Indicator | SKIL | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 31.34 | 50.32 |
| Support Level | $3.72 | $6.54 |
| Resistance Level | $4.84 | $8.46 |
| Average True Range (ATR) | 0.47 | 0.48 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 0.45 | 37.93 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.